Resources

PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO).

Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE

Fundraising, collaboration, IP and leadership in focus as founders and investors shared practical advice for scaling in the UK

Coulter Partners successfully led a search for Neumirna Therapeutics and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer.

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.

The UK BioIndustry Association (BIA) is delighted to announce Professor Chris Molloy has taken up his role as Chief Executive Officer.

Coulter Partners successfully led a search assignment for Laigo Bio and is pleased to announce the placement of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO).

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

Coulter Partners successfully led a search assignment for Oral Care AB and is pleased to announce the placement of Lucas Kromann as Chief Executive Officer (CEO) Denmark.

Coulter Partners successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).

Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin Moses as Chair of the Board of Directors, with immediate effect.

Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.

International contract research organisation ChemPartner has officially opened its first European scientific hub at Discovery Park, Sandwich, Kent.

In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.

Epitopea announced the appointment of Lisa Butterfield to its Scientific Advisory Board (SAB).

Aravax has added Carsten Hellmann and Andrew Oxtoby to its board.